MediPharm will supply Medical Cannabis by Shoppers with oils, gel caps, and topicals.
Insulet's wearable insulin pumps will be integrated with blood glucose monitors from both companies.
The gene sequencing company's shares have been lagging. Will the situation be different a year from now?
Management warned that the COVID-19 outbreak will affect next quarter's results, but did not speculate as to how big the impact would be.
The company will replace its Omnipod DASH Personal Diabetes Managers next month to correct a software problem.
Cost-cutting led to a surprise profit, and the company outlined the path ahead for its pipeline treatment for ovarian cancer.
A huge acquisition could get this overlooked giant on investors' radar.
Lilly and Roche reported their latest disappointments in attempting to effectively treat Alzheimer's by attacking amyloid plaques.
Beam Therapeutics' new approach offers more precision than CRISPR.
Two drugs drove its fourth-quarter sales growth, and the company expects to have an experimental treatment for 2019n-CoV coronavirus in a few months.
A future blockbuster scores another success as AbbVie works to replace Humira losses.
The pharma giant will form a new publicly traded company out of its women's health and biosimilars businesses, and its legacy brands.
The company raised guidance, and also raised hopes about its vaccine candidate for African swine fever.
The integration of Shire is progressing more quickly than the company had expected.
The first approved drug for any food allergy may be the first of several from Aimmune Therapeutics.
Trouble sleeping is common among sufferers of Alzheimer's disease.
These companies offer growth at a reasonable price and could hold up in a downturn.
Reyvow is the first drug in an entirely new class of acute migraine treatments.
The impact of generic competition for Lyrica was expected, but investors saw other things in the quarterly report that concerned them.
Solid growth prospects make this animal health company an investor favorite, but don't forget to examine the price you'd pay.